MCID: SVR005
MIFTS: 49

Severe Pre-Eclampsia

Categories: Cardiovascular diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Severe Pre-Eclampsia

MalaCards integrated aliases for Severe Pre-Eclampsia:

Name: Severe Pre-Eclampsia 12 54 15 71 32
Severe Preeclampsia 12 15
Severe Pre-Eclampsia, Antepartum Condition or Complication 71
Severe Pre-Eclampsia, Postpartum Condition or Complication 71
Severe Pre-Eclampsia, with Delivery 12
Antepartum Severe Pre-Eclampsia 12
Postpartum Severe Pre-Eclampsia 12
Severe Toxemia 71

Classifications:



External Ids:

Disease Ontology 12 DOID:13129
ICD9CM 34 642.50
ICD10 32 O14.1
UMLS 71 C0156669 C0156672 C0156673 more

Summaries for Severe Pre-Eclampsia

Disease Ontology : 12 A pre-eclampsia that has symptom at least one of the following: SBP of 160mm HG or higher or DPB of 110mm HG or higher on 2 occasions at least 6 hours apart, proteinuria more than 5g in a 24-hour collection, pulmonary edema or cyanosis, oliguria, persistent headaches, epigastric pain and/or impaired liver function, thrombocytopenia, oligohydramnios, decreased fetal growth or placental abruption.

MalaCards based summary : Severe Pre-Eclampsia, also known as severe preeclampsia, is related to eclampsia and acute kidney failure, and has symptoms including at least one of the following An important gene associated with Severe Pre-Eclampsia is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Staphylococcus aureus infection. The drugs Dalteparin and Pseudoephedrine have been mentioned in the context of this disorder. Affiliated tissues include placenta, liver and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Severe Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Severe Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 350, show less)
# Related Disease Score Top Affiliating Genes
1 eclampsia 31.3 VEGFA SERPINC1 PGF PAPPA LGALS13 HLA-G
2 acute kidney failure 31.1 GPT CFH ALB
3 thrombotic microangiopathy 30.9 VEGFA CFH
4 pericardial effusion 30.7 VEGFA GPT ALB
5 hemolytic-uremic syndrome 30.6 CFH CFB C3
6 enterocolitis 30.6 CFH CFB C3
7 mild pre-eclampsia 30.6 VEGFA VCAM1 PGF PAPPA LGALS13 LEP
8 patau syndrome 30.6 PGF PAPPA LGALS13
9 hyperuricemia 30.4 LEP GPT ALB
10 membranoproliferative glomerulonephritis 30.4 CFH CFB C3 ALB
11 hypertensive encephalopathy 30.4 VEGFA PGF ALB
12 hellp syndrome 30.4 VEGFA SERPINC1 PGF LGALS13 LEP GPT
13 brain edema 30.3 VEGFA MMP9 ALB
14 cholelithiasis 30.3 LEP GPT ALB
15 kidney disease 30.2 VEGFA VCAM1 LEP CFH C3 ALB
16 leptin deficiency or dysfunction 30.2 LEP GPT ALB
17 antiphospholipid syndrome 30.2 VCAM1 SERPINC1 PGF F5 CFH C3
18 glomerulonephritis 30.2 VCAM1 FN1 CFH C3 ALB
19 proteasome-associated autoinflammatory syndrome 1 30.1 VCAM1 MMP9 ALB
20 disseminated intravascular coagulation 30.1 SERPINC1 GPT FN1 F5
21 amaurosis fugax 29.9 MMP9 F5
22 liver cirrhosis 29.9 SERPINC1 LEP GPT ALB
23 hemolytic anemia 29.8 CFH CFB C3 APOH
24 purpura 29.8 SERPINC1 C3 APOH
25 placental insufficiency 29.7 VEGFA SERPINC1 PGF PAPPA LEP FGR
26 cardiovascular system disease 29.6 VCAM1 SERPINC1 LEP APLN ALB
27 polyarteritis nodosa 29.6 VCAM1 GPT APOH
28 thrombotic thrombocytopenic purpura 29.5 SERPINC1 CFH C3 APOH
29 autoimmune disease 29.4 VCAM1 MMP9 HLA-G C3 APOH
30 thrombophilia due to thrombin defect 29.3 SERPINC1 F5 APOH
31 pre-eclampsia 29.2 VEGFA VCAM1 SERPINC1 PGF PAPPA MMP9
32 papilledema 29.1 VEGFA SERPINC1 APOH ALB
33 placental abruption 29.1 SERPINC1 PGF PAPPA HLA-G F5 APOH
34 hepatic infarction 29.1 SERPINC1 GPT APOH ALB
35 endocarditis 29.0 VCAM1 SERPINC1 APOH ALB
36 pulmonary embolism 29.0 SERPINC1 F5 APOH ALB
37 thrombophilia due to activated protein c resistance 28.9 SERPINC1 F5 APOH
38 antithrombin iii deficiency 28.9 SERPINC1 F5 APOH
39 hypertension, essential 28.8 VEGFA VCAM1 SERPINC1 PGF PAPPA MMP9
40 thrombosis 28.8 VCAM1 SERPINC1 F5 APOH
41 intracranial hypertension 28.8 SERPINC1 F5 APOH ALB
42 homocysteinemia 28.7 VCAM1 SERPINC1 F5 APOH ALB
43 protein s deficiency 28.7 SERPINC1 F5 APOH
44 thrombocytopenia 28.7 SERPINC1 GPT F5 CFH CFB C3
45 budd-chiari syndrome 28.6 SERPINC1 F5 APOH
46 blood coagulation disease 28.5 VEGFA SERPINC1 GPT F5 APOH ALB
47 stroke, ischemic 28.2 SERPINC1 MMP9 F5 APOH ALB
48 placenta disease 28.1 VEGFA SERPINC1 PGF PAPPA HLA-G F5
49 vascular disease 27.8 VEGFA VCAM1 SERPINC1 MMP9 LEP FN1
50 dipetalonemiasis 10.6 GPT ALB
51 multifocal choroiditis 10.6 CFH CFB
52 heterophyiasis 10.6 GPT ALB
53 dicrocoeliasis 10.5 GPT ALB
54 pyridoxine deficiency anemia 10.5 VCAM1 GPT
55 acroosteolysis 10.5 VEGFA ALB
56 intestinal perforation 10.5 VEGFA GPT ALB
57 choroiditis 10.5 VEGFA CFH CFB
58 apnea, obstructive sleep 10.5 VEGFA LEP ALB
59 pneumococcal meningitis 10.5 MMP9 C3
60 sick building syndrome 10.5 VEGFA MMP9 LEP
61 epidermolysis bullosa dystrophica, autosomal dominant 10.5 C3 ALB
62 hepatic tuberculosis 10.5 GPT ALB
63 atypical hemolytic uremic syndrome with complement gene abnormality 10.5 CFH CFB C3
64 dense deposit disease 10.5 CFH CFB C3
65 exanthem 10.5 VEGFA GPT ALB
66 genetic atypical hemolytic-uremic syndrome 10.5 CFH CFB C3
67 c3 glomerulopathy 10.5 CFH CFB C3
68 protein-energy malnutrition 10.5 LEP GPT ALB
69 chronic ulcer of skin 10.5 VEGFA FN1 ALB
70 prediabetes syndrome 10.5 LEP GPT ALB
71 pyuria 10.5 GPT C3 ALB
72 chronic venous insufficiency 10.5 VEGFA VCAM1 MMP9
73 dengue hemorrhagic fever 10.5 VEGFA GPT ALB
74 retinal drusen 10.5 CFH CFB C3
75 splenic abscess 10.5 GPT ALB
76 ascending cholangitis 10.4 GPT ALB
77 heart aneurysm 10.4 MMP9 GPT ALB
78 coronary aneurysm 10.4 MMP9 GPT ALB
79 klatskin's tumor 10.4 MMP9 GPT ALB
80 macular degeneration, age-related, 9 10.4 VCAM1 C3
81 dengue disease 10.4 VCAM1 GPT ALB
82 complement deficiency 10.4 CFH CFB C3
83 carotid stenosis 10.4 VEGFA VCAM1 MMP9
84 acalculous cholecystitis 10.4 GPT ALB
85 hair disease 10.4 VEGFA GPT ALB
86 granulomatous hepatitis 10.4 GPT ALB
87 microvascular complications of diabetes 1 10.4 VEGFA VCAM1 MMP9
88 pulmonary emphysema 10.4 VEGFA MMP9 ALB
89 lens disease 10.4 VEGFA CFH ALB
90 iga glomerulonephritis 10.4 CFH C3 ALB
91 pulmonary edema 10.4
92 glucose metabolism disease 10.4 VEGFA LEP GPT ALB
93 portal hypertension 10.4 VEGFA GPT ALB
94 secondary progressive multiple sclerosis 10.4 VEGFA MMP9 LEP ALB
95 acquired metabolic disease 10.4 VEGFA LEP GPT ALB
96 hemolytic uremic syndrome, atypical 1 10.3 CFH CFB C3
97 hepatic encephalopathy 10.3 MMP9 GPT ALB
98 respiratory distress syndrome in premature infants 10.3
99 newborn respiratory distress syndrome 10.3
100 alport syndrome 10.3 VEGFA CFH ALB
101 odontogenic myxoma 10.3 VEGFA MMP9
102 bacterial meningitis 10.3 MMP9 C3 ALB
103 decubitus ulcer 10.3 VEGFA MMP9 FN1 ALB
104 severe nonproliferative diabetic retinopathy 10.3 VEGFA PGF ALB
105 fournier gangrene 10.3 SERPINC1 ALB
106 corneal disease 10.3 VEGFA MMP9 FN1 ALB
107 sleep apnea 10.3 VEGFA VCAM1 LEP GPT ALB
108 macular retinal edema 10.3 VEGFA PGF ALB
109 meningitis 10.3 VEGFA MMP9 C3 ALB
110 endophthalmitis 10.3 VEGFA PGF ALB
111 gliosarcoma 10.3 VEGFA MMP9 FN1 ALB
112 intussusception 10.3 VEGFA PGF ALB
113 angiokeratoma circumscriptum 10.3 VEGFA MMP9
114 retinal perforation 10.3 VEGFA PGF FN1
115 lyme disease 10.3 MMP9 CFH C3
116 lipid storage disease 10.3 LEP GPT ALB
117 suppression of tumorigenicity 12 10.3 VEGFA MMP9 FN1 ALB
118 trypanosomiasis 10.3 VCAM1 HLA-G GPT C3 ALB
119 gastrointestinal tuberculosis 10.3 GPT ALB
120 acute pyelonephritis 10.3 PGF GPT ALB
121 retinal detachment 10.3
122 hydatidiform mole, recurrent, 1 10.3
123 yemenite deaf-blind hypopigmentation syndrome 10.3
124 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 10.3
125 hydrops, lactic acidosis, and sideroblastic anemia 10.3
126 gestational trophoblastic neoplasm 10.3
127 pyelonephritis 10.3 PGF GPT ALB
128 atherosclerosis susceptibility 10.2 VEGFA VCAM1 MMP9 LEP ALB
129 arteries, anomalies of 10.2 VEGFA VCAM1 MMP9 LEP ALB
130 protein-losing enteropathy 10.2 VEGFA SERPINC1 ALB
131 ectopic pregnancy 10.2 VEGFA PGF PAPPA
132 hepatic coma 10.2 SERPINC1 GPT ALB
133 blood protein disease 10.2 VEGFA SERPINC1 ALB
134 esophageal varix 10.2 SERPINC1 GPT ALB
135 intermediate coronary syndrome 10.2 VCAM1 SERPINC1 ALB
136 compartment syndrome 10.2 SERPINC1 GPT ALB
137 background diabetic retinopathy 10.2 VEGFA VCAM1 PGF ALB
138 acquired angioedema 10.2 F5 C3
139 hypersplenism 10.2 SERPINC1 GPT ALB
140 kawasaki disease 10.2 MMP9 GPT ALB
141 kuhnt-junius degeneration 10.2 VEGFA PGF CFH CFB
142 cancer-associated retinopathy 10.2 VEGFA PGF
143 deficiency anemia 10.2
144 asphyxia neonatorum 10.2
145 chromosomal triplication 10.2
146 limb ischemia 10.2 VEGFA PGF MMP9
147 microvascular complications of diabetes 5 10.2 VEGFA VCAM1 PGF ALB
148 pulmonary fibrosis, idiopathic 10.2 VEGFA VCAM1 MMP9 FN1 ALB
149 blood group, globoside system 10.2 VEGFA PGF FN1 ALB
150 bullous retinoschisis 10.2 VEGFA F5 CFH
151 alpha-1-antitrypsin deficiency 10.2 SERPINC1 GPT ALB
152 pneumonia 10.2 VEGFA MMP9 GPT FN1 ALB
153 moyamoya disease 1 10.2 VEGFA SERPINC1 MMP9
154 diabetes mellitus, insulin-dependent 10.2 VEGFA VCAM1 LEP CFB C3 ALB
155 exudative vitreoretinopathy 1 10.1 VEGFA PGF FN1 ALB
156 hepatic vascular disease 10.1 VEGFA SERPINC1 GPT ALB
157 preretinal fibrosis 10.1 VEGFA FN1
158 myeloma, multiple 10.1 VEGFA VCAM1 MMP9 FN1 ALB
159 pain agnosia 10.1
160 rickets 10.1
161 oligohydramnios 10.1
162 persistent fetal circulation syndrome 10.1 VEGFA PGF LEP HLA-G ALB
163 respiratory failure 10.1
164 cortical blindness 10.1
165 thrombophilia 10.1
166 triploidy 10.1
167 headache 10.1
168 partial hydatidiform mole 10.1
169 autoimmune atherosclerosis 10.1 VCAM1 APOH
170 muscular disease 10.1 VEGFA MMP9 LEP GPT FN1 ALB
171 retinal vascular disease 10.0 VEGFA VCAM1 PGF FN1 ALB
172 venous insufficiency 10.0 VEGFA VCAM1 MMP9 F5
173 degeneration of macula and posterior pole 10.0 VEGFA PGF CFH CFB C3
174 arteriosclerosis 10.0 VCAM1 SERPINC1 MMP9 GPT
175 creatinine clearance quantitative trait locus 10.0
176 amnestic disorder 10.0
177 placenta praevia 10.0
178 end stage renal failure 10.0
179 chronic kidney disease 10.0
180 sticky platelet syndrome 10.0 SERPINC1 F5
181 atrial standstill 1 10.0
182 coarctation of aorta 10.0
183 renal cell carcinoma, nonpapillary 10.0
184 migraine with or without aura 1 10.0
185 pheochromocytoma 10.0
186 neural tube defects 10.0
187 preeclampsia/eclampsia 1 10.0
188 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
189 thrombocytopenia-absent radius syndrome 10.0
190 helicobacter pylori infection 10.0
191 patent ductus arteriosus 1 10.0
192 preeclampsia/eclampsia 4 10.0
193 preeclampsia/eclampsia 5 10.0
194 peripartum cardiomyopathy 10.0
195 adrenal gland pheochromocytoma 10.0
196 cardiac arrest 10.0
197 hemiplegia 10.0
198 adult respiratory distress syndrome 10.0
199 hemopericardium 10.0
200 cardiac tamponade 10.0
201 gestational diabetes 10.0
202 nephrotic syndrome 10.0
203 acute kidney tubular necrosis 10.0
204 hypothyroidism 10.0
205 cranial nerve palsy 10.0
206 congestive heart failure 10.0
207 scotoma 10.0
208 fatty liver disease 10.0
209 47,xyy 10.0
210 prothrombin-related thrombophilia 10.0
211 sickle cell disease 10.0
212 48,xyyy 10.0
213 bronchopulmonary dysplasia 10.0
214 cytokine deficiency 10.0
215 diploid-triploid mosaicism 10.0
216 encephalopathy 10.0
217 hypoxia 10.0
218 acute myocardial infarction 9.9 SERPINC1 PAPPA MMP9 FN1
219 cryoglobulinemia 9.9 GPT FN1 APOH
220 aplastic anemia 9.9 VEGFA VCAM1 SERPINC1 FN1 ALB
221 post-thrombotic syndrome 9.9 VCAM1 SERPINC1 F5
222 hydrops fetalis, nonimmune 9.9
223 myasthenia gravis 9.9
224 ocular motor apraxia 9.9
225 body mass index quantitative trait locus 1 9.9
226 aspiration pneumonia 9.9
227 chorioamnionitis 9.9
228 endometritis 9.9
229 pancytopenia 9.9
230 von willebrand's disease 9.9
231 amenorrhea 9.9
232 acute pancreatitis 9.9
233 anuria 9.9
234 liver disease 9.9
235 systemic scleroderma 9.9
236 hyperglycemia 9.9
237 pancreatitis 9.9
238 postpartum depression 9.9
239 inflammatory myopathy with abundant macrophages 9.9
240 nonarteritic anterior ischemic optic neuropathy 9.9 VEGFA SERPINC1 F5
241 syphilis 9.9 GPT FN1 APOH ALB
242 body mass index quantitative trait locus 11 9.8 VEGFA VCAM1 LEP GPT CFH C3
243 coronary artery anomaly 9.8 VEGFA VCAM1 SERPINC1 MMP9 GPT ALB
244 ovarian hyperstimulation syndrome 9.8 VEGFA SERPINC1 F5 ALB
245 may-thurner syndrome 9.8 F5 APOH
246 autoimmune disease of musculoskeletal system 9.8 C3 APOH ALB
247 acanthamoeba keratitis 9.8 F5 APOH
248 homocystinuria 9.8 SERPINC1 F5 ALB
249 branch retinal artery occlusion 9.8 VEGFA SERPINC1
250 afibrinogenemia, congenital 9.8 SERPINC1 F5 C3
251 splenic infarction 9.8 SERPINC1 GPT APOH
252 alzheimer disease 9.7
253 total anomalous pulmonary venous return 1 9.7
254 colorectal cancer 9.7
255 fibromuscular dysplasia 9.7
256 hypercholesterolemia, familial, 1 9.7
257 hypertriglyceridemia, familial 9.7
258 chromosome 2q35 duplication syndrome 9.7
259 down syndrome 9.7
260 anemia, autoimmune hemolytic 9.7
261 insulin-like growth factor i 9.7
262 anxiety 9.7
263 graft-versus-host disease 9.7
264 spastic paraplegia, intellectual disability, nystagmus, and obesity 9.7
265 adrenal cortical carcinoma 9.7
266 metabolic acidosis 9.7
267 paraganglioma 9.7
268 paroxysmal nocturnal hemoglobinuria 9.7
269 dextro-looped transposition of the great arteries 9.7
270 polycystic kidney disease 9.7
271 glucose intolerance 9.7
272 renal hypertension 9.7
273 gastric ulcer 9.7
274 malignant hypertension 9.7
275 choledocholithiasis 9.7
276 multicentric reticulohistiocytosis 9.7
277 allergic hypersensitivity disease 9.7
278 acute cystitis 9.7
279 cholestasis 9.7
280 mitral valve stenosis 9.7
281 optic nerve disease 9.7
282 sex cord-gonadal stromal tumor 9.7
283 myeloproliferative neoplasm 9.7
284 thrombocytosis 9.7
285 iron metabolism disease 9.7
286 lipid metabolism disorder 9.7
287 neurilemmoma 9.7
288 neurilemmoma of the fifth cranial nerve 9.7
289 aspiration pneumonitis 9.7
290 ischemia 9.7
291 cellulitis 9.7
292 hemoglobinuria 9.7
293 paraplegia 9.7
294 hyperthyroidism 9.7
295 periodontitis 9.7
296 appendicitis 9.7
297 polyhydramnios 9.7
298 lung disease 9.7
299 neuropathy 9.7
300 autosomal dominant polycystic kidney disease 9.7
301 krukenberg carcinoma 9.7
302 hypoglycemia 9.7
303 pulmonary venous return anomaly 9.7
304 depression 9.7
305 nonsyndromic paraganglioma 9.7
306 dysphagia 9.7
307 bicornuate uterus 9.7
308 pik3ca-related overgrowth syndrome 9.7
309 meningococcemia 9.7 SERPINC1 F5
310 pregnancy loss, recurrent 1 9.7 HLA-G F5 APOH
311 peripheral vascular disease 9.7 VEGFA VCAM1 SERPINC1 F5 ALB
312 catastrophic antiphospholipid syndrome 9.6 F5 CFH APOH
313 sagittal sinus thrombosis 9.6 SERPINC1 F5
314 malaria 9.6 VEGFA VCAM1 SERPINC1 MMP9 GPT CFH
315 cerebral sinovenous thrombosis 9.6 F5 APOH
316 varicose veins 9.6 VEGFA SERPINC1 MMP9 FN1 F5
317 takayasu arteritis 9.6 VCAM1 SERPINC1 MMP9 APOH
318 puerperal pulmonary embolism 9.6 SERPINC1 PGF APOH
319 macular degeneration, age-related, 1 9.5 VEGFA PGF MMP9 FN1 CFH CFB
320 blood platelet disease 9.5 VEGFA SERPINC1 GPT APOH ALB
321 spinal cord infarction 9.4 SERPINC1 F5 APOH
322 sudden sensorineural hearing loss 9.4 SERPINC1 F5 APOH
323 eye disease 9.4 VEGFA VCAM1 PGF MMP9 FN1 CFH
324 prothrombin deficiency, congenital 9.4 SERPINC1 F5 APOH
325 sneddon syndrome 9.4 SERPINC1 F5 APOH
326 intracranial thrombosis 9.4 SERPINC1 F5 APOH
327 peripheral vertigo 9.4 SERPINC1 F5 APOH
328 factor xii deficiency 9.4 SERPINC1 F5 APOH
329 purpura fulminans 9.4 SERPINC1 F5 APOH
330 legg-calve-perthes disease 9.4 SERPINC1 F5 APOH
331 cerebrovascular disease 9.4 VCAM1 MMP9 LEP F5 APOH
332 portal vein thrombosis 9.4 SERPINC1 F5 APOH
333 protein c deficiency 9.4 SERPINC1 F5 APOH
334 diabetes mellitus, noninsulin-dependent 9.3 VEGFA VCAM1 PGF MMP9 LEP GPT
335 vein disease 9.3 VEGFA SERPINC1 PGF GPT F5 ALB
336 central retinal vein occlusion 9.3 VEGFA SERPINC1 F5 APOH
337 retinal vein occlusion 9.3 VEGFA SERPINC1 F5 APOH
338 intermittent claudication 9.3 VEGFA SERPINC1 PGF APOH ALB
339 thrombophlebitis 9.3 SERPINC1 F5 APOH ALB
340 inflammatory bowel disease 9.3 VEGFA VCAM1 SERPINC1 MMP9 LEP HLA-G
341 patent foramen ovale 9.3 SERPINC1 F5 APOH ALB
342 systemic lupus erythematosus 9.3 VEGFA VCAM1 MMP9 CFH CFB C3
343 diabetes mellitus 9.2 VEGFA VCAM1 SERPINC1 PAPPA MMP9 LEP
344 behcet syndrome 9.2 SERPINC1 F5 APOH ALB
345 ischemic colitis 9.2 VEGFA SERPINC1 MMP9 F5 APOH
346 pulmonary artery disease 9.1 VEGFA SERPINC1 GPT F5 APOH ALB
347 retinal vascular occlusion 9.0 VEGFA SERPINC1 PGF F5 APOH
348 retinal artery occlusion 9.0 VEGFA SERPINC1 PGF F5 APOH
349 heart disease 8.9 VEGFA VCAM1 SERPINC1 PGF MMP9 LEP
350 myocardial infarction 8.3 VEGFA VCAM1 SERPINC1 PGF PAPPA MMP9

Graphical network of the top 20 diseases related to Severe Pre-Eclampsia:



Diseases related to Severe Pre-Eclampsia

Symptoms & Phenotypes for Severe Pre-Eclampsia

Symptoms:

12 (showing 1, show less)
  • at least one of the following

MGI Mouse Phenotypes related to Severe Pre-Eclampsia:

45 (showing 10, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 ALB APLN C3 CFB CFH F5
2 homeostasis/metabolism MP:0005376 10.31 ALB APLN APOH C3 CFB CFH
3 immune system MP:0005387 10.18 ALB C3 CFB CFH FGR FN1
4 hematopoietic system MP:0005397 10.17 C3 CFB CFH FGR FN1 HLA-G
5 embryo MP:0005380 10.11 APLN C3 F5 FN1 LEP PGF
6 liver/biliary system MP:0005370 9.87 ALB C3 F5 FN1 LEP SERPINC1
7 muscle MP:0005369 9.86 ALB APLN C3 CFH FN1 LEP
8 normal MP:0002873 9.81 ALB C3 CFB CFH FGR FN1
9 renal/urinary system MP:0005367 9.56 ALB C3 CFB CFH LEP MMP9
10 skeleton MP:0005390 9.28 C3 CFB FGR FN1 GPT LEP

Drugs & Therapeutics for Severe Pre-Eclampsia

Drugs for Severe Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 158, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4 9005-49-6
2
Pseudoephedrine Approved Phase 4 90-82-4 7028
3
Ephedrine Approved Phase 4 299-42-3 9294
4
Enoxaparin Approved Phase 4 9005-49-6 772
5
leucovorin Approved Phase 4 58-05-9 6006 143
6
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
7
Clonidine Approved Phase 4 4205-90-7 2803
8
Captopril Approved Phase 4 62571-86-2 44093
9
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
10
Azithromycin Approved Phase 4 83905-01-5 55185 447043
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
12 Pharmaceutical Solutions Phase 4
13 Antibodies Phase 4
14 Immunoglobulins Phase 4
15 Antibodies, Antiphospholipid Phase 4
16 Anti-Infective Agents Phase 4
17 Heparin, Low-Molecular-Weight Phase 4
18 Adrenergic Agonists Phase 4
19 Adrenergic alpha-2 Receptor Agonists Phase 4
20 Sympatholytics Phase 4
21 Central Nervous System Stimulants Phase 4
22 Vasoconstrictor Agents Phase 4
23 Trace Elements Phase 4
24 Micronutrients Phase 4
25 Vitamin B Complex Phase 4
26 Vitamin B9 Phase 4
27 Nutrients Phase 4
28 Hematinics Phase 4
29 Folate Phase 4
30 Natriuretic Agents Phase 4
31 diuretics Phase 4
32 Sodium Potassium Chloride Symporter Inhibitors Phase 4
33 Angiotensin-Converting Enzyme Inhibitors Phase 4
34 Iron Supplement Phase 4
35 Lactoferrin Phase 4
36 Anti-Asthmatic Agents Phase 4
37 Respiratory System Agents Phase 4
38 Nasal Decongestants Phase 4
39 Bronchodilator Agents Phase 4
40
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
41
Misoprostol Approved Phase 3 59122-46-2 5282381
42
Oxytocin Approved, Vet_approved Phase 3 50-56-6 439302 53477758
43
Carbetocin Approved, Investigational Phase 3 37025-55-1 71715 16681432
44
Digoxin Approved Phase 2, Phase 3 20830-75-5 30322 2724385
45
Nicardipine Approved, Investigational Phase 3 55985-32-5 4474
46
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
47
Titanium dioxide Approved Phase 3 13463-67-7
48
Povidone Approved Phase 3 9003-39-8
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
50 Urapidil Investigational Phase 3 34661-75-1
51 Citrate Phase 2, Phase 3
52 Chelating Agents Phase 2, Phase 3
53 Sildenafil Citrate Phase 2, Phase 3 171599-83-0
54 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3
55 Phosphodiesterase Inhibitors Phase 2, Phase 3
56 Anti-Ulcer Agents Phase 3
57 Oxytocics Phase 3
58 Gastrointestinal Agents Phase 3
59 Antacids Phase 3
60 Acetylsalicylic acid lysinate Phase 3
61 Immunoglobulin Fab Fragments Phase 2, Phase 3
62 Anesthetics, Local Phase 3
63 Serotonin Agents Phase 3
64 Serotonin Receptor Agonists Phase 3
65 Anti-Inflammatory Agents Phase 3
66 Cyclooxygenase Inhibitors Phase 3
67 Anti-Inflammatory Agents, Non-Steroidal Phase 3
68 Analgesics, Non-Narcotic Phase 3
69 Antipyretics Phase 3
70 Antirheumatic Agents Phase 3
71 Fibrinolytic Agents Phase 3
72 Platelet Aggregation Inhibitors Phase 3
73
Ethyl cellulose Phase 3 9004-57-3 24832091
74
Triacetin Phase 3 102-76-1 5541
75
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
76
Hydralazine Approved Phase 2 86-54-4 3637
77
Dexmedetomidine Approved, Vet_approved Phase 2 113775-47-6 68602 5311068
78
Remifentanil Approved Phase 2 132875-61-7 60815
79
Acetaminophen Approved Phase 2 103-90-2 1983
80
Ibuprofen Approved Phase 2 15687-27-1 3672
81
Heparin Approved, Investigational Phase 2 9005-49-6 772 46507594
82
Ketorolac Approved Phase 2 74103-06-3, 66635-83-4 3826
83
Oxycodone Approved, Illicit, Investigational Phase 2 76-42-6 5284603
84
Pravastatin Approved Phase 2 81093-37-0 54687
85
Certolizumab pegol Approved Phase 2 428863-50-7
86 Rosuvastatin Calcium Phase 1, Phase 2 147098-20-2
87 Digitalis Phase 2
88 Hypnotics and Sedatives Phase 2
89 Hypolipidemic Agents Phase 2
90 Anticholesteremic Agents Phase 2
91 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
92 Lipid Regulating Agents Phase 2
93 Antimetabolites Phase 2
94 Immunologic Factors Phase 2
95 calcium heparin Phase 2
96 Narcotics Phase 2
97 Analgesics, Opioid Phase 2
98 Ketorolac Tromethamine Phase 2
99 Immunosuppressive Agents Phase 2
100 Angiogenesis Inducing Agents Phase 2
101
Methocarbamol Approved, Vet_approved Phase 1 532-03-6 4107
102 Neuromuscular Agents Phase 1
103
Methyldopa Approved 555-30-6 38853
104
Protein C Approved
105
Nimodipine Approved, Investigational 66085-59-4 4497
106
Hydrocortisone acetate Approved, Vet_approved 50-03-3
107
Hydrocortisone Approved, Vet_approved 50-23-7 5754
108
Tocopherol Approved, Investigational 1406-66-2, 54-28-4 14986
109
Methyltestosterone Approved 58-18-4 6010
110
Testosterone Approved, Experimental, Investigational 58-22-0, 481-30-1 6013 10204
111
Testosterone undecanoate Approved, Investigational 5949-44-0
112
Testosterone enanthate Approved 315-37-7 9416
113
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
114
Bupivacaine Approved, Investigational 38396-39-3, 2180-92-9 2474
115
Thrombin Approved, Investigational
116
Ergocalciferol Approved, Nutraceutical 50-14-6 5280793
117
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
118
Vitamin D3 Approved, Nutraceutical 67-97-0 6221 5280795
119
Aspartic acid Approved, Nutraceutical 56-84-8 5960